The U.S. FDA authorized the first interchangeable biosimilar insulin, signaling a sea change in the biopharmaceutical industry.The recognition of the interchangeability is likely to positively impact Korean companies planning to enter the U.S. biosimilar market, observers said.On Wednesday, the FDA
Korean biotech companies are increasingly establishing a scientific advisory committee to speed up global new drug development and enhance R&D capabilities.An advisory group of experts can help the entire new drug development cycle, including developing new pipelines, discovering candidate substance
People who showed allergic reactions, including anaphylaxis to the first dose of mRNA Covid-19 vaccines by Pfizer or Moderna, can tolerate the second dose, a study said.U.S. researchers released the study results, titled, “Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Pa
The financial reports of Japanese pharmaceutical companies operating in Korea showed they remitted large amounts of dividends to their headquarters, while offering little in social contributions.According to audit reports submitted by the Korean branches of nine Japan-based multinational pharmaceuti
Curocell, a domestic biotech startup, said Monday that its CAR-T treatment, CRC01, showed complete response in diffuse large B-cell lymphoma patients with relapsed or refractory diffuse large B-cell lymphoma after receiving two systemic chemotherapies.The company will present the interim result of t
Not only pharmaceuticals but food and cosmetic industries are paying keen attention to the microbiome sector.Microbiome, a combination of words “microbiota” and “genome,” refers to collecting all microorganisms such as bacteria, viruses, and fungi.Microbiome-related products used to be confined to h
3billion, a biotechnology company that makes a genome-based diagnosis on rare diseases using artificial intelligence, has developed a new deep-learning model, which detects more genetic mutations with twice higher probability than the existing model.3billion announced Wednesday that their research r
Samsung Bioepis said Tuesday that it has entered phase 3 clinical trials of SB17, a biosimilar drug of Stelara (ingredient: ustekinumab), for treating patients with moderate to severe plaque psoriasis.The company began its multinational study in eight countries, including Korea, Poland, and the Czec
GC LabCell will merge GC Cell to diversify portfolios and expand the business to lead the global cell therapy market.They held board meetings on Friday and decided to merge into one company to significantly enhance global competitiveness by combining different specialized skills in cell therapy, the
It is necessary to understand the body's mechanism accurately to deliver micro ribonucleic acid or deoxyribonucleic acid substances targeting genetic diseases.Ewha Womans University Graduate School of Pharmaceutical Sciences Professor Lee Hyuk-jin made the point while explaining the development of R
Coreline Soft, a medical image software developer, said Wednesday that it would supply its solutions to Chinese and Taiwanese hospitals, following its recent participation in the largest lung cancer diagnosis project in Europe.Coreline Soft will provide its AVIEW COPD solution to the People’s Hospit
U.S. President Joe Biden’s policy to promote biosimilar drugs to lower the overall drug price is expected to benefit Korean biosimilar makers such as Celltrion and Samsung Bioepis.On Friday, Biden signed the Executive Order on Promoting Competition in the American Economy, news reports said. The exe
Theragen Bio said Tuesday that it has obtained a domestic patent for a genetic sequence method to predict neoantigen to develop a vaccine for cancers.The patented technology uses artificial intelligence to predict the binding affinity and immunogenicity of human leukocyte antigen (HLA) Class 2, a ma
Arbor Med, a bio venture company that develops new drugs for rare and incurable diseases, said Tuesday that it opened a research and development center in Pangyo, Gyeonggi Province."With the opening of the R&D center, the company expects to accelerate the development of its intractable rare disease
“The more severe the metabolic syndrome is, the higher the risk of dementia rises.”That was the conclusion of a joint research team that analyzed the correlations between metabolic syndrome and the risk of dementia incidence, according to a news release issued by Seoul St. Mary’s Hospital on Monday.
Machine learning algorithms that can predict the treatment response of the immunotherapy based on the cancer patient’s clinical information have been developed.Theragenbio said Friday that it has developed an algorithm that can predict non-small cell lung cancer (NSCLC) patient’s immunotherapy respo
Corelinesoft plans to present “AVIEW Modeler,” an artificial intelligence-based 3D anatomy software, at the annual congress of the Korea Orthopaedic Association from July 8-10.AVIEW Modeler follows four functions; image segmentation with Magic Cut, STL auto-generation and auto-calibration capabiliti
Hugel aims to expand its domain to liquid polymer filler business to move beyond botulinum toxin and HA filler and grow into a total medical esthetic company.Hugel signed a memorandum of understanding (MOU) with Dexlevo on Wednesday to secure the exclusive sales rights for liquid polymer filler, a m
The Korea Institute of Radiological Medical Sciences (KIRAMS) said Wednesday that its research team has tracked down the routes traveled by ingested microplastics (MP) in the human body for the first time in the world.The research team, led by Drs. Kim Jin-su and Kang Choong-mo, made the discovery u
Athenex recently discussed with the U.S. Food and Drug Administration how to supplement deficiencies raised by the FDA in its complete response letter (CRL) in February concerning the clinical trials of oral paclitaxel. At the meeting held in the second quarter, Athenex, Hanmi Pharmaceutical’s U.S.